Does trontinemab represent the next generation of anti-amyloid monoclonal antibodies thanks to Brainshuttle technology? New research looks encouraging.

In his brand new video series, Frank A. Clark, MD, sits down with an expert to discuss parental leave and how it relates to psychiatry.

"Doctors in their lonely rounds, Poets with their sacred sounds, Human kindness that abounds shout, nothing stops the spring."

The Ethics Committee of the American Psychiatric Association has released its 2025 edition of their opinions on the principles of medical ethics. What is our ethical way forward?

How does John Kane, MD, address issues of cognition in schizophrenia?

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

This variable use of official and unofficial psychiatric diagnoses for political reasons leaves us with a conundrum…

How can psychiatry avoid foolishness and be more like Shakespeare's fools?

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

Here’s how we can best stand up to hatred…

Do you want to be featured in a future Special Report? Check out our April theme!

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Yesterday marked a somber National Doctors’ Day…

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.